Hormone regulation and hormone antagonist effects on protein patterns of human endometrial secretion during receptivity.
Endometrial receptivity is a particular stage of maturation during the luteal phase to permit implantation. We have studied endometrial protein secretion and its patterns evaluated by SDS-PAGE, laser densitometry and Western blots. Uterine secretion electrophoresis (USE) permits highly sophisticated analyses of the intrauterine milieu and allows clinical determination of the receptive stage of the endometrium. This technique reveals direct parameters by patterns of numerous individual protein bands, mainly resolved between 68.0 and 6.5 kD. Characteristic bands appear during the typical functional states of the menstrual cycle presenting evidence on the diagnostic capacity of this method to identify stages of adequate (= normal) or inadequate (= defective) luteal phase maturation. Several individual protein bands appear as characteristic markers for the receptive stage of the luteal phase. We have isolated and molecularly identified several of these proteins: histones H2A, H2B, H3 and H4. In order to identify the endocrine dependency of the protein bands, which significantly contribute to the "receptive stage pattern," patients were treated with the progesterone antagonist RU 486 at day LH +2. The assessment 4 days later revealed deficient USE patterns, particularly diminished and missing bands of the H2A-, H2B-, and H3-histones. These results demonstrate progesterone-dependent components of the endometrium at the receptive stage, which can be used as useful markers for an improved precision in luteal phase diagnostics. On the other hand, essential parts of the protein pattern may serve as new targets for successful contraceptive interventions ("endometrial contraception").
Department of Anatomy and Reproductive Biology, RWTH University of Aachem, Germany.
K
K
Beier-Hellwig
K
K
Sterzik
B
B
Bonn
U
U
Hilmes
M
M
Bygdeman
K
K
Gemzell-Danielsson
H M
HM
Beier
D000818:Animals; D004591:Electrophoresis, Polyacrylamide Gel; D010064:Embryo Implantation / Q000502:physiology*; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology*; D006728:Hormones / Q000502:physiology*; D006801:Humans; D007247:Infertility, Female / Q000503:physiopathology; D011247:Pregnancy; D011506:Proteins / Q000378:metabolism*
D006727:Hormone Antagonists; D006728:Hormones; D011506:Proteins